fbpx

Studies

Join a study.
Help find a cure.

Every medical breakthrough we celebrate and benefit from is because of volunteers just like you. Everyday people who say “yes” to participating in clinical trials are changing the world for the better.

Explore our open studies — each one represents an opportunity to help build healthier futures.

Select a condition
to view the relevant open studies

Filter by Condition
Additional Filters

Lung Research Studies

We’re validating a blood test to screen for lung cancer. We hope this innovative new test may one day indicate if you need further evaluation. Early detection matters. Detecting cancer early can improve treatment outcomes and survival. The 5-year survival rate for lung cancer is 8x higher if found before it spreads!  

Preliminary Qualifications

  • Current or former smoker
  • Age 50 years or older
  • Have scheduled or are willing to schedule a low-dose CT scan

“AHEAD” Alzheimer’s Prevention

If you're worried that your memory might start fading, then joining an Alzheimer's prevention study might be a great option for you. It might just help future generations too. This study examines whether a new drug may help to slow or prevent the onset of Alzheimer's disease in those with elevated risk of developing the disease.

Preliminary Qualifications

  • 65-80 years of age.
  • Normal memory and thinking.
  • Have not been diagnosed with Alzheimer’s disease.

AriBio Early Alzheimer’s Trial

The purpose of this study is to find out if the study drug, called AR1001, can help people with Alzheimer’s Disease. Some research has shown that people with Alzheimer’s Disease have damage to the blood vessels in their brain. It is thought that AR1001 may help the blood vessels in your brain work better.

Preliminary Qualifications

  • 55-80 years of age.
  • Mild cognitive impairment or mild dementia consistent with Alzheimer's disease.
  • A history of subjective memory decline with gradual onset in the last 3 years.

Colorectal Cancer Blood Test

We are validating Signal-C®, a blood-based diagnostic test to screen for colorectal cancer, in hopes this innovative new test may one day indicate if you need further evaluation.

Preliminary Qualifications

  • 45-84 years of age
  • Have, or will have, an upcoming colonoscopy
  • Considered by a physician or healthcare provider as being of 'average risk' for colorectcal cancer
  • Willing to consent to blood draw prior to bowel preparation and undergoing colonoscopy

Altimmune NASH Study

This study is for people with a diagnosis of non-alcoholic steatohepatitis (NASH), which is a condition that causes liver inflammation and damage due to a buildup of fat in the liver. The investigational drug, pemvidutide, is being developed as a possible treatment for NASH.

Preliminary Qualifications

  • 18-75 years of age.
  • Diagnosis of NASH.
  • BMI greater than or equal to 27.

“LMI” Tau Detection Study

The purpose of this study is to investigate the effectiveness and safety of a new injection—given in conjunction with a PET scan—to help detect tau protein in the brain. Early detection could help with the diagnostic process, as well as the treatment of, Alzheimer's disease.

Preliminary Qualifications

  • 50+ years of age.
  • A projected life expectancy of less than or equal to 1 year.
  • Study includes brain scan (PET scan).

Amyloid Plaque “AbbVie” Alzheimer’s Study

Amyloid plaques in the brain may be the main cause of Alzheimer's disease. This study is to determine if a new drug can reduce amyloid plaques and slow disease progression.

Preliminary Qualifications

  • 50-90 years of age.
  • Diagnosis of mild-to-moderate Alzheimer's disease.

Sensory Stimulation Alzheimer’s “Cognito” Study

The main purpose of this study is to see whether daily use of a device called the "Sensory Stimulation System" can help people with Alzheimer's-related memory problems. The device provides sensory stimulation via glasses worn on the face and headphones worn over the ears.

Preliminary Qualifications

  • 50-85 years of age.
  • Diagnosis of mild-to-moderate Alzheimer's disease.

Obesity “GZBM” Study

Obesity is a complex disease with many underlying causes and impacts on health. This study is to test a new drug with the potential to deliver substantial body weight reduction across the spectrum of obesity.

Preliminary Qualifications

  • Must be at least 18 years of age.
  • BMI greater than 35.

“AACM” Alzheimer’s Prevention

If you're worried that your memory might start fading, then joining an Alzheimer's prevention study might be a great option for you. This study examines whether a new drug may help to slow or prevent the onset of Alzheimer's disease in those with elevated risk of developing the disease.

Preliminary Qualifications

  • 65-80 years of age.
  • Normal memory and thinking.
  • Blood test (given at Charter) indicates elevated risk of developing Alzheimer's.

“Avanir” Alzheimer’s Agitation Trial

This study evaluates a new medication to treat agitation in people with Alzheimer's disease. It is hoped this potential treatment could reduce caregiver burden and improve overall disease prognosis.

Preliminary Qualifications

  • 50-90 years of age.
  • Sometimes experience feelings of agitation.
  • Diagnosis of Alzheimer’s disease.

“CELIA” Alzheimer’s Trial

This study tests a new investigational medication for the treatment of Alzheimer's disease.  The drug is hoped to work by targeting and preventing the accumulation of tau tangles.

Preliminary Qualifications

  • 50-80 years of age.
  • Have mild cognitive impairment due to Alzheimer's disease, or mild Alzheimer's disease.

“Merck” Early Alzheimer’s Disease Trial

In this trial, an investigational drug is used to target tau proteins to reduce or stop their spread and slow the progression of Alzheimer's disease.

Preliminary Qualifications

  • 50-80 years of age.
  • Have mild cognitive impairment due to Alzheimer's disease, or mild or moderate Alzheimer's disease.

“Cerevel 002” Parkinson’s Disease Trial

We're testing an oral medication called Tavapadon as a possible treatment for Parkinson's disease over 35 weeks. Tavapadon aims to improve motor control symptoms.

Preliminary Qualifications

  • 40-80 years of age.
  • Have been diagnosed with Parkinson's disease within the last 3 years.

“Precision” NASH Trial

This quick study is to collect blood samples from people with various stages of fatty liver disease or NASH to support advancements in medical diagnoses of diseases such as fatty liver disease and NASH.

Preliminary Qualifications

  • 18 years of age or older.

Schedule Your Assessment

Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.

Sign Up Now

Your contact information

Do you live in Central Florida?

Preferred Charter Research location

I would like to receive the Charter Research newsletter.

Comments (not required)

This field is for validation purposes and should be left unchanged.